Definium Therapeutics, Inc.

NASDAQ:DFTX

Biotechnology

Healthcare
$29.12 -1.67%

-$0.41 today

Market cap
$3.99B
Beta
2.38
P/E (TTM)
-11.0
EPS (TTM)
-$2.18
52W Low $12.88High $26.15

Volume 1.91M

Average 2.67M

DFTX Operating Income

Profit from core operations after operating expenses, before interest and taxes.

Definium Therapeutics, Inc.NASDAQ: DFTX

Operating Income · Q3 FY2026 · quarter ended Sep 2026

Operating income remains negative

Q3 FY2026 operating income was -$72.28M, compared with -$45.67M a year earlier. Trailing-twelve-month operating income was -$254.15M.

Context

  • Operating income grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether operating income reaches the consensus estimate of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the -60.0% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterSep 2026
-$72.28M+3.7% QoQ
Last fiscal yearDec 2025
-$166.31M-60.0% YoY
LTMSep 2026
-$254.15M-68.1% YoY
Operating Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-58.3%+100.0%+158.3 pp
1 year-60.0%+100.0%+160.0 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Operating Income history

USD · from the income statement

Latest · FY2025
(166.31M) USD
Year-over-year change
-60.0%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Operating Income vs competitors

How DFTX compares with its peers on the latest reported figures

  • Peers report in different currencies, so operating income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -68.1% is the 8th highest of 10, against a peer median of -29.4%.
DFTX Competitors
Operating Income for DFTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ANROAlto Neuroscience, Inc.LTM Mar 2026$54.9M USD+178.5%——
ATHEAlterity Therapeutics LimitedFY2025-A$14.57M AUD+25.6%—268.0%
NERVMinerva Neurosciences, Inc.LTM Jun 2026-$35.14M USD-117.4%——
LBRXLB Pharmaceuticals Inc Common StockLTM Mar 2026-$46.86M USD———
GHRSGH Research PLCLTM Mar 2026-$66.69M USD-29.4%——
RAPPRapport Therapeutics, Inc. Common StockLTM Mar 2026-$122.21M USD-31.3%—611.0%
AXSMAxsome Therapeutics, Inc.LTM Jun 2026-$188.54M USD+17.6%—24.3%
MPLTMapLight Therapeutics, Inc.LTM Mar 2026-$210.04M USD-140.9%——
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026-$223.08M USD+18.7%——
DFTXDefinium Therapeutics, Inc.LTM Sep 2026-$254.15M USD-68.1%——
PRAXPraxis Precision Medicines, Inc.LTM Sep 2026-$406.72M USD-38.8%——
Peer median (excluding DFTX) —-29.4%—268.0%

Competitors are the stored peer set for DFTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue003.16M527K0
Gross Profit00(3.16M)(527K)0
Gross Margin—————
Research & Development34.79M36.17M48.96M65.3M117.67M
Selling, General & Admin59.07M30.16M41.74M38.62M48.64M
Operating Expenses93.85M66.33M90.7M103.39M166.31M
Depreciation & Amortization2.62M3.18M3.16M527K0
EBITDA(91.22M)(52.12M)(92.57M)(105.87M)(178.31M)
EBITDA Margin—————
Operating Income(93.85M)(66.33M)(93.87M)(103.92M)(166.31M)
Operating Margin—————
Interest Income01.5M5.58M11.56M10.96M
Interest Expense359K1.5M920K2.28M5.48M
Other Income / Expenses(339K)9.54M(1.87M)(4.76M)(17.48M)
Income Before Tax(94.19M)(56.8M)(95.73M)(108.68M)(183.79M)
Pre-Tax Margin—————
Income Tax Expense(1.16M)0000
Net Income(93.04M)(56.8M)(95.73M)(108.68M)(183.79M)
Net Margin—————
EPS (Basic)(3.40)(1.53)(2.44)(1.54)(2.06)
EPS (Diluted)(3.40)(1.53)(2.44)(0.15)(2.06)
Weighted Avg Shares27.38M30.86M39.16M70.46M89.33M
Weighted Avg Shares (Diluted)27.38M30.86M39.16M704.61M89.33M

Definium Therapeutics, Inc.

NASDAQ:DFTX

Intrinsic Alpha fair value

Locked

Current Price

$29.12

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.